Fig. 1
From: Anti-Axl antibody treatment reduces the severity of experimental autoimmune encephalomyelitis
α-Axl antibody significantly reduces the clinical course and severity of MOG-induced EAE. C57Bl/6J mice were injected intraperitoneally (IP) with PBS, IgG isotype control, or α-Axl-activating antibody at 8 days post-MOG immunization. Mice were monitored daily, and the clinical index (CI) was recorded (n = 13–17/group). The clinical course of male (a) and female (b) mice during acute and chronic EAE. The number of days male (c) and female (d) mice maintained a CI ≥ 3. e Percentage of mice with a CI ≥ 3. Statistical significance represents the comparison of IgG versus α-Axl-treated mice. *p ≤ 0.05 and **p ≤ 0.01, Mann-Whitney U test